Keyword: Zydelig

14. Venclexta

AbbVie and Roche's Venclexta is a first-in-class BCL-2 inhibitor that made its debut in 2016 in the U.S. for the treatment of patients with relapsed chronic lymphocytic leukemia caused by a particular genetic mutation.